Herpes simplex virus-2 in the genital mucosa: Insights into the mucosal host response and vaccine development

Current Opinion in Infectious Diseases

Volumn 25, Issue 1, 2012, Pages 92-99

  Lee, Amanda J ^a   Ashkar, Ali A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Adaptive; Herpes simplex virus 2; Innate; Mucosal immunity; Vaccine

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HERPES SIMPLEX VACCINE; INTERFERON; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; REGULATORY T LYMPHOCYTE; REVIEW; VIRAL CLEARANCE; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; GENITALIA; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; HUMANS; IMMUNITY, INNATE; INTERFERONS; KILLER CELLS, NATURAL; MALE; MUCOUS MEMBRANE; TOLL-LIKE RECEPTORS;

EID: 84155167028     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834e9a56     Document Type: Review

References (71)

1. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. J Am Med Assoc 2006; 296:964-973.
2. Centers for Disease Control and Prevention (CDC). Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years: United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2010; 59:456-459.
3. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-850.
4. Koelle DM, Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 2008; 59:381-395.
5. Caviness AC, Demmler GJ, Selwyn BJ. Clinical and laboratory features of neonatal herpes simplex virus infection: a case-control study. Pediatr Infect Dis J 2008; 27:425-430.
6. Zuckerman R, Wald A. Herpes simplex virus infections in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl. 4):S104-S107.
7. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl JMed 2007; 356:790-799.
8. Gray RH, Li X, Wawer MJ, et al. Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis 2004; 189:1209-1215.
9. Uematsu S, Akira S. Innate immune recognition of viral infection. Uirusu 2006; 56:1-8.
10. Beutler B, Hoebe K, Du X, Ulevitch RJ. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 2003; 74:479-485.
11. Gill N, Deacon PM, Lichty B, et al. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of toll-like receptor ligands correlates with beta interferon production. J Virol 2006; 80:9943-9950.
12. Thatte A, Dewitte-Orr SJ, Lichty B, et al. A critical role for IL-15 in TLRmediated innate antiviral immunity against genital HSV-2 infection. Immunol Cell Biol 2011; 89:663-669.
13. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511.
14. Gill N, Chenoweth MJ, Verdu EF, Ashkar AA. NK cells require type I IFN receptor for antiviral responses during genital HSV-2 infection. Cell Immunol 2011; 269:29-37.
15. Conrady CD, Halford WP, Carr DJJ. Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection. J Virol 2011; 85:1625-1633.
16. Iijima N, Mattei LM, Iwasaki A. Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. Proc Natl Acad Sci U S A 2011;108:284-289.
17. Martinez J, Huang X, Yang Y. Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo. J Immunol 2008; 180:1592-1597.
18. Swann JB, Hayakawa Y, Zerafa N, et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007; 178:7540-7549.
19. Nakayama Y, Plisch EH, Sullivan J, et al. Role of PKR and type I IFNs in viral control during primary and secondary infection. PLoS Pathog 2010;6:e1000966.
20. Gill N, Ashkar AA. Adaptive immune responses fail to provide protection against genital HSV-2 infection in the absence of IL-15. Eur J Immunol 2007; 37:2529-2538.
21. Lund JM, Linehan MM, Iijima N, Iwasaki A. Cutting edge: plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection in situ. J Immunol 2006; 177:7510-7514.
22. Rasmussen SB, Sorensen LN, Malmgaard L, et al. Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J Virol 2007; 81:13315-13324.
23. Dalloul A, Oksenhendler E, Chosidow O, et al. Severe herpes virus (HSV-2) infection in two patients with myelodysplasia and undetectable NK cells and plasmacytoid dendritic cells in the blood. J Clin Virol 2004; 30:329-336.
24. Zhao X, Deak E, Soderberg K, et al. Vaginal submucosal dendritic cells, but not langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J Exp Med 2003; 197:153-162.
25. Donaghy H, Bosnjak L, Harman AN, et al. Role for plasmacytoid dendritic cells in the immune control of recurrent human herpes simplex virus infection. J Virol 2009; 83:1952-1961.
26. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008; 9:503-510.
27. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2:907-916.
28. Ashkar AA, Rosenthal KL. Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol 2003; 77:10168-10171.
29. Thapa M, Kuziel WA, Carr DJJ. Susceptibility of CCR5-deficient mice to genital herpes simplex virus type 2 is linked to NK cell mobilization. J Virol 2007; 81:3704-3713.
30. Ank N, Iversen MB, Bartholdy C, et al. An important role for type III interferon (IFN-/IL-28) in TLR-induced antiviral activity. J Immunol 2008; 180:2474-2485.
31. Iversen MB, Ank N, Melchjorsen J, Paludan S.R. Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs. J Virol 2010; 84:4579-4586.
32. Ank N, West H, Bartholdy C, et al. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80:4501-4509.
33. Morrison LA, Zhu L, Thebeau LG. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J Virol 2001; 75:1195-1204.
34. ParrMB, Parr EL. Immunity to vaginal herpes simplex virus-2 infection in B-cell knockout mice. Immunology 2000; 101:126-131.
35. Dudley KL, Bourne N, Milligan GN. Immune protection against HSV-2 in B-cell-deficient mice. Virology 2000; 270:454-463.
36. Harandi AM, Svennerholm B, Holmgren J, Eriksson K. Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J Gen Virol 2001; 82 (Pt 4):845-853.
37. Corey L, Langenberg AGM, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. J Am Med Assoc 1999; 282:331-340.
38. Iijima N, Linehan MM, Zamora M, et al. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J Exp Med 2008; 205:3041-3052.
39. Li Z, Palaniyandi S, Zeng R, et al. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci U S A 2011; 108:4388-4393.
40. Coleman CA, Muller-Trutwin MC, Apetrei C, Pandrea I. T regulatory cells: aid or hindrance in the clearance of disease? J Cell Mol Med 2007; 11:1291-1325.
41. Diaz GA, Koelle DM. Human CD4+ CD25 high cells suppress proliferative memory lymphocyte responses to herpes simplex virus type 2. J Virol 2006; 80:8271-8273.
42. Fernandez MA, Puttur FK, Wang YM, et al. T regulatory cells contribute to the attenuated primary CD8+ and CD4+ T cell responses to herpes simplex virus type 2 in neonatal mice. J Immunol 2008; 180:1556-1564.
43. Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of early protective immunity to viral infection by regulatory T cells. Science 2008; 320:1220-1224.
44. Dobbs ME, Strasser JE, Chu CF, et al. Clearance of herpes simplex virus type 2 by CD8+ T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanisms. J Virol 2005; 79:14546-14554.
45. Koelle DM, Posavad CM, Barnum GR, et al. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998; 101:1500-1508.
46. Parr MB, Parr EL. Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes. J Virol 1998; 72:2677-2685.
47. Schiffer JT, Abu-Raddad L, Mark KE, et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A 2010; 107:18973-18978.
48. Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007; 204:595-603.
49. Tang VA, Rosenthal KL. Intravaginal infection with herpes simplex virus type-2 (HSV-2) generates a functional effector memory T cell population that persists in the murine genital tract. J Reprod Immunol 2010; 87 (1-2):39-44.
50. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009; 462:510-513.
51. Gill N, Ashkar AA. Overexpression of interleukin-15 compromises CD4- dependent adaptive immune responses against herpes simplex virus 2. J Virol 2009; 83:918-926.
52. Milligan GN, Bernstein DI, Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 1998; 160:6093-6100.
53. Milligan GN, Bernstein DI. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 1997; 229:259-268.
54. Cohen J. Immunology: painful failure of promising genital herpes vaccine. Science 2010; 330:304.
55. Ye L, Zeng R, Bai Y, et al. Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol 2011; 29:158-163.
56. Koelle DM, Magaret A, McClurkan CL, et al. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naive and HSV-2-infected subjects. Clin Vaccine Immunol 2008;15:773-782.
57. Zhang X, Chentoufi AA, Dasgupta G, et al. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol 2009; 2:129-143.
58. Olson K, Macias P, Hutton S, et al. Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male mice. Vaccine 2009; 28:548-560.
59. Lindqvist M, Persson J, Thorn K, Harandi AM. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol 2009; 182:6435-6443.
60. Cattamanchi A, Posavad CM, Wald A, et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol 2008; 15:1638-1643.
61. Morello CS, Levinson MS, Kraynyak KA, Spector DH. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol 2011;85:3461-3472.
62. Halford WP, Puschel R, Gershburg E, et al. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One 2011; 6:e17748.
63. Hoshino Y, Pesnicak L, Dowdell KC, et al. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 2009; 200:1088-1095.
64. Vagvala SP, Thebeau LG, Wilson SR, Morrison LA. Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replicationdefective herpes simplex virus type 2 vaccine in immunocompetent mice. J Virol 2009; 83:953-960.
65. Akhrameyeva NV, Zhang P, Sugiyama N, et al. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J Virol 2011; 85:5036-5047.
66. Natuk RJ, Cooper D, Guo M, et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol 2006; 80:4447-4457.
67. McGhee J.R. A mucosal gateway for vaccines. Nat Biotechnol 2011; 29:136-138.
68. Dasgupta G, Benmohamed L. Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates? Vaccine 2011; 29:5824-5836.
69. Bhavanam S, Snider DP, Kaushic C. Intranasal and subcutaneous immunization under the effect of estradiol leads to better protection against genital HSV-2 challenge compared to progesterone. Vaccine 2008; 26:6165-6172.
70. Hughes GC, Thomas S, Li C, et al. Cutting edge: progesterone regulates IFN-alpha production by plasmacytoid dendritic cells. J Immunol 2008; 180:2029-2033.
71. Stadnisky MD, Xie X, Coats ER, et al. Self MHC class I-licensed NK cells enhance adaptive CD8 T-cell viral immunity. Blood 2011; 117:5133-5141.